PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.\', \'Department of Infectious Disease, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.\', \'Department of Infectious Disease, Shohada Pakdasht Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.\', \'Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Scinces, Tehran, Iran.\', \'Department of Infectious Disease, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.\', \'Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.\', \'Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts. Electronic address: mfholick@bu.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1530-891X(21)01259-310.1016/j.eprac.2021.09.016
?:doi
?:hasPublicationType
?:journal
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
is ?:pmid of
?:pmid
?:pmid
  • 34653608
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all